Pyng Medical Corp.
TSX VENTURE : PYT

Pyng Medical Corp.

June 05, 2006 09:00 ET

Pyng Forges Strategic Training Equipment Alliances

RICHMOND, BRITISH COLUMBIA--(CCNMatthews - June 5, 2006) - Kevin O'Neill, CEO of Pyng Medical Corp. (TSX VENTURE:PYT), is pleased to announce new developments to facilitate FAST1™ caregiver training in the use of the FAST1™ to better address the market demand created by the recent changes to the management of cardiac arrest guidelines. Working with Pyng, Simulaids Inc. and Lifeform™ NASCO, have developed life-like manikins for increased realistic training of caregivers in the use of the FAST1™ adult intraosseous device.

The first product that will come to the marketplace in mid-June is a simulator from Simulaids, Inc., Saugerties, New York. This trainer which is anatomically accurate enables students to insert the FAST1™ catheter into a simulated patient manubrium, the target area of the device. This simple and compact model will retail for under US$100 and will enable hundreds of training uses with replaceable disk inserted under the simulated "patient" skin.

An image of the simulator from Simulaids, Inc. may be viewed on CCNMatthews' website at: http://www.ccnmatthews.com/docs/prod1.jpg.

Later this summer a more comprehensive training system from Lifeform™ NASCO, Ft. Atkinson, Wisconsin will be available. This model will include a manikin and a complete FAST1™ training system. Larger than the model developed by Simulaids, this manikin will enable students to utilize the FAST1™ device utilizing an anatomically correct simulator. It will also enable students to aspirate simulated blood from the manubrium marrow cavity and infuse intravenous fluids. This comprehensive training system will come to the market at US$1,250.

An image of the training system from Lifeform™ NASCO may be viewed on CCNMatthews' website at: http://www.ccnmatthews.com/docs/prod2.jpg.

With the recent changes to the management of cardiac arrest guidelines, Pyng Medical expects the use of the FAST1™ Intraosseous Infusion device to increase. Intraosseous infusion has proven equivalency to conventional IV and central line applications in the delivery of critical cardiac medications. The FAST1™ does not interfere with manual or device assisted CPR compressions and is the option of choice for many EMS providers.

Lifeform™ NASCO and Simulaids each have approximately 200 distributors worldwide. Pyng Medical's relationship with these leading training supply companies and their sales staff is expected to facilitate FAST1™ sales in existing and new markets.

Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", "projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contact Information